SCHEMBL6035477

SCHEMBL6035477

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1c(CC(=O)O)cccc1C(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
TIPARP Q7Z3E1 1/20 0.33
GCG P01275 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
PPARG P37231 1/20 0.32
LIPE Q05469 2/20 0.32
HDAC4 P56524 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
PPARD Q03181 3/20 0.32
PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035210 0.91 GCGR (0.36) GCGRPTGDR2L3MBTL1SMN1; SMN2KDM4E
SCHEMBL6035752 0.90 SMN1; SMN2 (0.41) SMN1; SMN2KDM4ELMNAHPGDPPARG
SCHEMBL6036239 0.90 HDAC4 (0.35) GCGRL3MBTL1SMN1; SMN2KDM4ELMNA
SCHEMBL6035417 0.90 SMN1; SMN2 (0.36) GCGRSMN1; SMN2KDM4ELMNAHPGD
SCHEMBL6035945 0.90 GCGR (0.35) GCGRSMN1; SMN2KDM4ELMNAHPGD
SCHEMBL6034571 0.89 GCGR (0.35) GCGRL3MBTL1SMN1; SMN2KDM4ELMNA
SCHEMBL6035540 0.88 PPARG (0.40) GCGRSMN1; SMN2KDM4ELMNAHPGD
SCHEMBL6034630 0.87 GCGR (0.34) GCGRPTGDR2SMN1; SMN2KDM4ELMNA
SCHEMBL6035208 0.86 HCRTR1 (0.38) GCGRSMN1; SMN2KDM4ELMNAHCRTR1
SCHEMBL6035863 0.85 PPARD (0.41) PTGDR2SMN1; SMN2KDM4ELMNAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885PTGDR2 4688/4885L3MBTL1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.